The Latest on Acute Lymphocytic Leukemia
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
2022 BURST Year in Review™: Reflecting on Recent Evidence for Testing in Patients with GI Cancers
Updates in Myelodysplastic Syndromes
Clinical Vignettes™: Integrating Novel CAR T-Cell Therapies Across Lymphoid Malignancies with an Eye Toward the Future of Care
Expert Illustrations and Commentaries™: Evaluating the Potential for Novel Mechanistic Approaches to Overcome Clinical Gaps in the Care of Patients with LR-MDS
European Approval Sought for Cilta-cel in Relapsed and Lenalidomide-Refractory MyelomaMay 26th 2023
A Type II variation application seeking the approval of ciltacabtagene autoleucel in adult patients with relapsed and lenalidomide-refractory multiple myeloma has been submitted to the European Medicines Agency.
EMA Recommends Approval of Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLCMay 26th 2023
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab as neoadjuvant therapy in combination with platinum-based chemotherapy for patients with resectable non–small cell lung cancer at high risk of recurrence and tumor cell PD-L1 expression of at least 1%.
Durvalumab Plus Chemotherapy With or Without Olaparib Improves PFS in Advanced Endometrial CancerMay 26th 2023
The combination of durvalumab and platinum-based chemotherapy, followed by maintenance therapy with either durvalumab plus olaparib or durvalumab alone, elicited a statistically significant and clinically meaningful improvement in progression-free survival in patients with newly diagnosed, advanced or recurrent endometrial cancer.
Fox Chase Physician Wins Best Poster Award at Breast Cancer Meeting for Research on Surgery to Remove Lymph NodesMay 26th 2023
Austin D. Williams, MD, MSEd, of Fox Chase Cancer Center, received the Best Poster Award at the recent 24th Annual Meeting of the American Society of Breast Surgeons.
Quizartinib Garners Approval in Japan for Newly Diagnosed FLT3-ITD+ AMLMay 26th 2023
Japan’s Ministry of Health, Labour, and Welfare has approved quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation and as maintenance monotherapy in patients with newly diagnosed acute myeloid leukemia whose tumors harbor FLT3-ITD mutations.
Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing DisparitiesMay 25th 2023
Study findings demonstrated that states that expanded Medicaid had improved survival rates in patients with pancreatic and gastric cancers, with greater improvements in Black patients for some analyses.
Luspatercept Nearly Doubles Likelihood of Transfusion Independence in Lower-Risk MDSMay 25th 2023
Luspatercept-aamt led to a higher rate of sustained transfusion independence compared with erythropoiesis stimulating agents in patients with ESA-naïve, lower-risk myelodysplastic syndrome.
Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical CancerMay 25th 2023
Pembrolizumab plus chemotherapy with or without bevacizumab led to a substantial improvement in overall survival vs placebo plus chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the KEYNOTE-826 trial.
Minimally Invasive Distal Pancreatectomy Provides Effective Alternative in Resectable Pancreatic CancerMay 25th 2023
Minimally invasive distal pancreatectomy was found to be a safe and effective alternative to that of open distal pancreatectomy in patients with resectable pancreatic cancer, confirmed by a noninferior radical resection rate, lymph node yield, and comparable survival data.
Gottschalk and Krenciute Discuss the Development of CAR T-cell Therapy in Pediatric Solid TumorsMay 25th 2023
Drs Gottschalk and Krenciute discuss the difficulties of translating successes with CAR T-cell therapy in adults to the pediatric population; ongoing research with investigational products that could reduce T-cell exhaustion, burnout, and the time from bench to bedside; and expectations for the future of cellular therapy in oncology.
Advances in Precision Medicine Propel Personalized GI Cancer CareMay 25th 2023
Eileen O’Reilly, MD, and Benjamin Weinberg, MD, discuss the importance of conducting biomarker testing as the gastrointestinal cancer treatment arena continues to evolve, the need for increased gene fusion testing, and the negative effects of inadequate biomarker testing in the gastrointestinal cancer population.
Powerful Chemotherapy Drug Reaches Brain Tumors Using Novel Ultrasound TechnologyMay 25th 2023
Northwestern Medicine scientists report results of the first in-human clinical trial in which they used a novel, skull-implantable ultrasound device to open the blood-brain barrier and repeatedly permeate large, critical regions of the human brain to deliver chemotherapy that was injected intravenously.
NCCN Guidelines Endorse FES PET for Workup of Recurrent/Metastatic ER+ Breast CancerMay 25th 2023
The National Comprehensive Cancer Network Guidelines now recommend the use of 18F-Fluorestradiol positron emission tomography in certain circumstances during the systemic staging workup for patients with recurrent or metastatic for estrogen receptor–positive breast cancer.
Clinical Trials in Endometrial Cancer Need Improved Diversity to Address Rising Mortality RatesMay 25th 2023
Bhavana Pothuri, MD, expands on challenges that still need to be addressed for the treatment of patients with endometrial cancer, highlights potential practice-changing data from the phase 3 NRG-GY018 and RUBY trials, details the evolving role of PARP inhibitors for patients with ovarian cancer, and touches on key emerging data from trials for patients with cervical cancer.
Sitravatinib Plus Nivolumab Fails to Meet OS End Point in Nonsquamous NSCLCMay 25th 2023
The combination of sitravatinib and nivolumab did not meet the primary end point of overall survival compared with docetaxel as second- or third-line treatment for patients with advanced nonsquamous non–small cell lung cancer who progressed on prior chemotherapy and immune checkpoint inhibitor therapy.
METTL3 Controls Splicing Factor Abundance and Aids Progression in CLLMay 24th 2023
Yiming Wu, PhD, discusses the rationale for studying splicing defects in patients with chronic lymphocytic leukemia without spliceosome mutations, shared key findings from this study, and emphasized how these findings support further research with METTL3 in chronic lymphocytic leukemia and other hematologic malignancies with RNA splicing dysregulation.
Research on Novel Targets and Potential Risk Factors Drives Improvements in the Management of GI CancersMay 24th 2023
Gastrointestinal oncology experts discuss current strategies and novel developments in gastrointestinal cancers, the role of intestinal dysbiosis and gastrointestinal carcinogenesis, germline genetic features in appendiceal cancer, and the need for anticipatory, multidisciplinary guidance in clinical practice.
Ongoing Investigation of RLY-4008 Highlights Evolving Treatment Options for FGFR2+ CholangiocarcinomaMay 24th 2023
R. Kate Kelley, MD, details the ongoing investigation of RLY-4008 for patients with advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements, other ongoing investigations in cholangiocarcinoma, and the importance of molecular testing to drive treatment decisions in this population.
Yale Cancer Center and Smilow Cancer Hospital Physicians and Scientists Presenting Latest Advances at 2023 ASCO Annual MeetingMay 24th 2023
Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology, June 2nd to June 6th at McCormick Place in Chicago, Illinois.
Voruciclib With or Without Venetoclax Shows Safety, Activity in R/R AML, B-cell MalignanciesMay 24th 2023
Voruciclib monotherapy and in combination with venetoclax demonstrated clinical activity and was well tolerated with no significant myelosuppression in heavily pretreated patients with relapsed/refractory acute myeloid leukemia or B-cell malignancies, according to initial data from a phase 1 trial.
NCCN Guidelines List Ropeginterferon Alfa-2b as Preferred Treatment in Polycythemia VeraMay 24th 2023
The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been revised to include ropeginterferon alfa-2b-njft as a preferred treatment option for patients with high- and low-risk polycythemia vera, irrespective of treatment history.